养阴解毒合剂治疗冠心病合并新型冠状病毒感染临床疗效分析

Clinical Efficacy Analysis of Yangyin Jiedu Mixture in Treatment of Coronary Heart Disease with COVID-19

目的:探讨养阴解毒合剂治疗冠心病合并新型冠状病毒感染患者的有效性和安全性。方法:选择2022年12月10日-2023年2月28日贵州中医药大学第一附属医院心内科收治的63例冠心病合并新型冠状病毒感染患者,随机分为实验组(31例)和对照组(32例)。对照组给予常规基础治疗,实验组在对照组的基础上口服养阴解毒合剂,15mL/次,3次/天。两组患者治疗周期均为7天,评估临床疗效,比较两组患者治疗前后胸痛VAS评分、中医证候积分及炎症指标水平变化。结果:治疗后,实验组总有效率为100%,显著高于对照组的87.5%(P<0.05);治疗后实验组心电图总疗效率为90.32%,与对照组68.75%相比,差异具有统计学意义(P<0.05);治疗后,两组患者血清白细胞介素-6(IL-6)、C反应蛋白(CRP)、中性粒细胞/淋巴细胞比率(NLR)、高敏肌钙蛋白T(cTnT-hs)水平、中医证候积分、胸痛VAS评分均较治疗前明显降低(P<0.05),且治疗后实验组下降更为显著(P<0.05)。结论:养阴解毒合剂治疗冠心病合并新型冠状病毒感染患者具有较好的临床疗效,可明显改善患者症状及胸痛程度,降低CRP、NLR、IL-6水平及中医证候积分。

Objective:To explore the clinical efficacy and safety of Yangyin Jiedu Mixture in the treatment of coronary heart disease with COVID-19.Methods:63 patients of coronary heart disease with COVID-19 admitted to Department of Cardiovascular Medicine of the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine from December 10,2022 to February 28,2023 were randomly divided into control group and experimental group,with 31 patients in the experimental group and 32 in the control group.The patients in control group were given conventional basic treatment.The patients in experimental group were oral administered with Yangyin Jiedu Mixture on the basis of the control group,15mL/time,3 times/day.Both groups were treated for 7 days.Calculating clinical efficacy,and comparison of changes in VAS scores of chest pain,TCM symptom scores and levels of inflammatory indicators before and after treatment in the two groups.Results:After treatment,the total effective rate of the experimental group was 100%,and significantly higher than 87.5%in the control group(P<0.05).The overall ECG efficacy rate of the post-treatment experimental group was 90.32%,Statistically significant when compared with 68.75%in the control group(P<0.05).Post-treatment,For patients in both groups,serum interleukin-6(IL-6),C reactive protein(CRP),neutrophil/lymphocyte ratio(NLR),high-sensitive troponin T(cTnT-hs)level,chest pain VAS score and TCM syndrome score were significantly lower compared with before treatment(P<0.05),the experimental group showed a more significant decrease in IL-6,CRP,NLR,TCM symptom score and VAS score of chest pain than the control group after treatment.Conclusion:Yangyin Jiedu Mixture in treatment of coronary heart disease with COVID-19 has a certain clinical effect,which can significantly improve the symptoms and chest pain,and reduce the level of CRP,NLR,IL-6 and TCM syndrome score.